Connor MJ, Khoo V, Watson V, Ahmed HU. Radical treatment without cure: decision-making in oligometastatic prostate cancer. Eur Urol. 2021 Apr;79(4):558-60. doi: 10.1016/j.eururo.2021.01.029
Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, Molnar I, Sherrill B. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. Int J Colorectal Dis. 2012 May 1;27(5):623-34.
Odom D, Barber B, Bennett L, Peeters M, Zhao Z, Kaye J, Wolf M, Wiezorek J. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011 Feb 1;26(2):173-81.
DiBenedetti DB, Gondek K, Sagnier PP, Kubin M, Keininger D, Marquis P. The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners. Eur Urol. 2005 Sep 1;48(3):503-11.
Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, Angelsen A, Girman CJ. Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. Eur Urol. 2001 Jan 1;39(1):36-41.
Kang Y, Bogerd HP, Yang J, Cullen BR. Analysis of the RNA binding specificity of the human tap protein, a constitutive transport element-specific nuclear RNA export factor. Virol J. 1999 Sep 15;262(1):200-9. doi: 10.1006/viro.1999.9906
Sorensen HT, Steffensen FH, Sabroe S, Rothman KJ, Gillman MW, Fischer P. Historical cohort study of in utero exposure to uterotonic drugs and cognitive function in young adult life. West J Med. 1999 Jan 1;170(5):260-2.